Z Forms A Phenoxy Alkyl Or Phenoxy Alkenyl Radical Patents (Class 514/543)
-
Patent number: 11759438Abstract: This invention features compositions, methods, and kits for treating conditions associated with pathological ocular neovascularization, reducing scarring in the eye, treating dry eye, treating macular degeneration, and treating keratitis by administering a serotonin receptor agonist.Type: GrantFiled: May 1, 2018Date of Patent: September 19, 2023Assignee: The Board of Supervisors of Louisiana StateInventors: Timothy Paul Foster, Charles David Nichols
-
Patent number: 11273191Abstract: The present disclosure relates to methods of administering a composition to a patient, particularly in the form of a dietary supplement, which addresses immune system deficiencies and promotes healthy immune system functioning. The present disclosure also related to compositions and methods for improving or boosting immune system functioning. The present disclosure further provides novel compositions for balancing immune response in human subjects.Type: GrantFiled: March 30, 2020Date of Patent: March 15, 2022Assignee: Script Essentials, LLCInventor: Suzy Cohen
-
Patent number: 11154533Abstract: Compositions and methods for treating skin conditions, ailments or diseases, such as autoinflammatory skin diseases such as psoriasis, dermatitis, pyoderma gangrenosum, palmoplantar pustulosis, prurigo nodularis and/or hidradenitis suppurativa, are described. The compositions comprise an agent that modulates the aryl hydrocarbon receptor, in particular an agent that agonizes the receptor. In one embodiment, the agent is indigo or a derivative of indigo, such as indirubin.Type: GrantFiled: March 5, 2021Date of Patent: October 26, 2021Assignee: Azora Therapeutics, Inc.Inventors: Matthew Davidson, Julie Saiki, Johan Andreasson
-
Patent number: 9539232Abstract: Disclosed is the therapeutic potential of Calebin A for osteoporosis (bone loss) caused by aging or chronic disease conditions like cancer. Calebin A is shown to down modulate osteoclastogenesis induced by receptor activator of nuclear factor (NF)-?B ligand (RANKL) signalling thereby having therapeutic potential for osteoporosis.Type: GrantFiled: August 4, 2016Date of Patent: January 10, 2017Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
-
Patent number: 9399631Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.Type: GrantFiled: October 18, 2013Date of Patent: July 26, 2016Assignees: UNIVERSITY OF SOUTH FLORIDA, MCGILL UNIVERSITY, THE HONG KONG POLYTECHNIC UNIVERSITYInventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
-
Patent number: 9220703Abstract: The novel therapeutic potential of Calebin A and compositions thereof to prevent pathological damage to mammalian articular cartilage is disclosed.Type: GrantFiled: January 10, 2014Date of Patent: December 29, 2015Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, Anjali Pandey
-
Patent number: 9216942Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.Type: GrantFiled: March 8, 2013Date of Patent: December 22, 2015Assignees: BAGI RESEARCH LIMITED, VERSITECH LIMITEDInventors: Allan Sik Yin Lau, Lai Hung Cindy Yang, Stanley Chi Chung Chik
-
Patent number: 9180110Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.Type: GrantFiled: August 27, 2014Date of Patent: November 10, 2015Assignee: Wockhardt Ltd.Inventors: Ramakant Kashinath Gundu, Narayanan Murali, Girish Kumar Jain
-
Publication number: 20150119458Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.Type: ApplicationFiled: April 25, 2013Publication date: April 30, 2015Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Hua Bai, Jian Hong, Lifeng Cai, Hegeng Wei, Xiaoyu Liu, Xiaohe Zheng
-
Patent number: 8933121Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).Type: GrantFiled: January 10, 2012Date of Patent: January 13, 2015Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Anjali Pandey
-
Publication number: 20140377342Abstract: The objective of this invention is to develop a novel wafer and capsule formulations using fenofibrate which is difficult to dissolve and control its release rate in vitro.Type: ApplicationFiled: December 14, 2012Publication date: December 25, 2014Inventor: Michael Li
-
Publication number: 20140364497Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.Type: ApplicationFiled: August 27, 2014Publication date: December 11, 2014Applicant: WOCKHARDT RESEARCH CENTREInventors: Ramakant Kashinath GUNDU, Narayanan Murali, Girish Kumar Jain
-
Patent number: 8852635Abstract: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.Type: GrantFiled: February 23, 2008Date of Patent: October 7, 2014Assignee: Wockhardt LtdInventors: Ramakant Kashinath Gundu, Narayanan Murali, Girish Kumar Jain
-
Publication number: 20140296336Abstract: A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation.Type: ApplicationFiled: December 22, 2011Publication date: October 2, 2014Applicant: ABBOTT GMBH & CO. KGInventors: Gunther Berndl, Juergen Weis, Dietrich Granzow, Bernd Liepold, Ute Lander, Ulrich Westedt
-
Publication number: 20140271845Abstract: Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Applicant: Cerovene, Inc.Inventors: Manish S. SHAH, Ray J. DiFalco
-
Publication number: 20140255479Abstract: The present invention provides pharmaceutical compositions suitable for oral and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Inventors: Stephen M. Carl, John Stanley Vrettos, William Stern
-
Publication number: 20140255480Abstract: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.Type: ApplicationFiled: April 7, 2014Publication date: September 11, 2014Applicant: ETHYPHARMInventors: Catherine HERRY, Pascal OURY
-
Publication number: 20140255450Abstract: The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.Type: ApplicationFiled: February 18, 2013Publication date: September 11, 2014Applicants: VERSITECH LIMITED, PURAPHARM COMPANY LIMITEDInventors: ALLAN SY LAU, LAI HUNG CINDY YANG, CHI CHUNG STANLEY CHIK, CHUN BONG JAMES LI
-
Publication number: 20140243378Abstract: Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described.Type: ApplicationFiled: October 19, 2012Publication date: August 28, 2014Applicants: Tufts Medical Center, Inc., Children's Medical Center CorporationInventors: Isabelle Draper, Louis M. Kunkel, Matthew S. Alexander, Alan S. Kopin
-
Publication number: 20140206674Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Markus ZWICKL
-
Patent number: 8778364Abstract: A nanodispersion containing nanoparticles having a mean size less than 300 nm dispersed in a vehicle that includes a water miscible solvent and water. The nanoparticles contain one or more drugs, a polymer and a surfactant, and the surfactant includes a mixture of fatty acids or its salts and sterol or its derivatives or its salts.Type: GrantFiled: June 18, 2010Date of Patent: July 15, 2014Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Ajay Jaysingh Khopade, Natarajan Arulsudar, Subhas Balaram Bhowmick
-
Patent number: 8778401Abstract: The present invention encompasses formulations and methods for producing solid dispersions comprising mesoporous materials with poorly aqueous soluble active ingredients. The active ingredient is formed in the amorphous state and entrapped in the nanosized pores of the mesoporous excipients using a co-spray drying process. The pore walls of mesoporous channels stabilize the amorphous form of active ingredient against re-crystallization. The amorphous active ingredient entrapped in mesoporous channels exhibits good stability during extended storage under stress test conditions and possesses significantly enhanced dissolution rates.Type: GrantFiled: February 18, 2009Date of Patent: July 15, 2014Assignee: Agency for Science, Technology and ResearchInventors: Shou-Cang Shen, Wai Kiong Ng, Leonard Chia
-
Patent number: 8772290Abstract: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of cells under hypoxic conditions, so that it can be used for preventing or treating of diseases such as cancer, arthritis, psoriasis, diabetic retinopathy and macular degeneration.Type: GrantFiled: April 21, 2011Date of Patent: July 8, 2014Assignee: Oscotech Inc.Inventors: Se-Won Kim, Jung Ho Kim, Se-Nyum Kim, Dae-Pil Kang, Youn Ho Han, Guo Fan Jin, Dong-Sik Jung, Sung-Ho Park, Ji Min Kim, Jhi Zheng
-
Publication number: 20140187617Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicant: AERIE PHARMACEUTICALS, INC.Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
-
Publication number: 20140171441Abstract: Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.Type: ApplicationFiled: December 17, 2013Publication date: June 19, 2014Applicant: BEND RESEARCH, INC.Inventors: Walter C. Babcock, Dwayne T. Friesen, Warren K. Miller, Daniel T. Smithey
-
Patent number: 8754125Abstract: The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives.Type: GrantFiled: October 4, 2011Date of Patent: June 17, 2014Assignee: The Medicines CompanyInventors: Min Ding, Rajeshwar Motheram, Glenn Sblendorio
-
Publication number: 20140161881Abstract: The present invention provides a reduced dose oral pharmaceutical composition comprising mixture of nanoparticulate fenofibrate and micronized fenofibrate and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: April 1, 2013Publication date: June 12, 2014Applicant: Lupin Atlantis Holdings, S.A.Inventors: Venkat Reddy KALLEM, Raghu Rami Reddy KASU, Subhasis DAS, Vijaya Kumar THOMMANDRU
-
Publication number: 20140162988Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140162987Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 8747875Abstract: An insecticidal composition comprising stabilized pyrethrins or pyrethroids is provided. Such composition includes stabilizing effective amount of N,N-dialkyl fatty acid amide solvents and certain ultraviolet-light absorbers. In such composition, the pyrethrins or pyrethroid can retain their insecticidal activity for an acceptably long period of time. Therefore, an advantage of this invention is to provide a topical pyrethrins or pyrethroid based insecticide which can remain effective in light over a long time period. Another advantage of this invention is to provide a stabilized topical pyrethrins or pyrethroid insecticide insecticidal formulation containing a high concentration of the active pyrethrins or pyrethroid ingredient to minimize the volume of formulation required.Type: GrantFiled: September 25, 2009Date of Patent: June 10, 2014Assignee: The Hartz Mountain CorporationInventors: W. Lance H. Hemsarth, Linda Valencia
-
Publication number: 20140134256Abstract: Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them.Type: ApplicationFiled: January 16, 2014Publication date: May 15, 2014Inventors: E. Itzhak LERNER, Vered ROSENBERGER, Moshe FLASHNER-BARAK, Anna DRABKIN, Naomi MOLDAVSKI
-
Publication number: 20140128353Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Biocopea LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 8653238Abstract: Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molecule. The transporter modulates the transport of the cargo across a biological barrier (e.g., a cell membrane) compared to the transport of the unconjugated cargo. Releasable linkers suitable for rapid and facile conjugation to various types of cargo and transporters are also disclosed, along with methods for using the linkers in the synthesis of conjugates.Type: GrantFiled: February 27, 2007Date of Patent: February 18, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Paul A. Wender, Elena A. Goun, Lisa R. Jones
-
Publication number: 20140038931Abstract: The purpose of present invention is to provide a medicine which has low contamination with a fine-pulverizing medium, is safe and has improved bioavailability. A method for producing a composite organic compound powder for medical use is used which comprises: mixing a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxyvinyl polymer and fine-pulverizing the organic compound powder; and removing at least the salt and the polyol during or after fine-pulverizing.Type: ApplicationFiled: August 27, 2013Publication date: February 6, 2014Applicant: ACTIVUS PHARMA CO., LTD.Inventors: Takashi HIROKAWA, Takahiro TADA, Jun NIHIRA
-
Patent number: 8642532Abstract: This invention is a method of using a class of excipients for protein formulation to reduce and/or eliminate protein aggregation in solutions or solids. This class of compounds contains carbonyl group(s) to form Schiff base(s) with amino groups of proteins and also contains moieties to keep protein molecules spatially separated. This method has never been disclosed anywhere in the literature.Type: GrantFiled: November 17, 2008Date of Patent: February 4, 2014Inventor: Guohan Yang
-
Publication number: 20130338160Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.Type: ApplicationFiled: June 18, 2013Publication date: December 19, 2013Inventors: Charles SHIH, Qian Shi, Hui-kang Wang
-
Publication number: 20130323304Abstract: Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.Type: ApplicationFiled: August 1, 2013Publication date: December 5, 2013Applicant: Banner Pharmacaps, Inc.Inventors: Aqeel Fatmi, Tae Kyoung Kim, Karla E. Madrigal
-
Patent number: 8592621Abstract: A description is given of precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease, in particular for the prevention or treatment of Type 2 diabetes. A description is also given of uses of these precursor compounds and edible compositions, preparations for nutrition or pleasure or semi-finished products and pharmaceutical preparations, containing such precursor compounds.Type: GrantFiled: July 15, 2010Date of Patent: November 26, 2013Assignee: Symrise AGInventors: Jakob Peter Ley, Michael Backes, Tobias Vössing, Frauke Stähler, Wolfgang Meyerhof, Christian Wintermeyer
-
Publication number: 20130303612Abstract: The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in a non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.Type: ApplicationFiled: February 25, 2013Publication date: November 14, 2013Applicant: Veloxis Pharmaceuticals A/SInventors: Per Holm, Tomas Norling
-
Patent number: 8580775Abstract: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.Type: GrantFiled: February 26, 2008Date of Patent: November 12, 2013Assignee: Cognis IP Management GmbHInventors: Thomas Markert, Philippe Moussou, Louis Danoux, Andreas Rathjens
-
Publication number: 20130295190Abstract: The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: New Jersey Institute of TechnologyInventors: Ecevit Bilgili, Rajesh Dave, Anagha Bhakay, Mohammad Azad
-
Patent number: 8575215Abstract: A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula: in which X, Y, A1, A2, R1, and R2 are defined herein.Type: GrantFiled: February 18, 2010Date of Patent: November 5, 2013Inventors: Yangsheng Du, Martin R. Farlow, Ruyu Du
-
Patent number: 8563607Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.Type: GrantFiled: October 11, 2011Date of Patent: October 22, 2013Assignees: University of South Florida, McGill University, The Hong Kong Polytechnic UniversityInventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
-
Publication number: 20130274297Abstract: The invention provides a composite of drug, polymeric carrier and at least one not cross linked polymer useful to improve the solubility of poorly water soluble drugs. The present invention comprises manufacturing process of this composite material. The manufacturing process is carried out by the solvent induced activation process, wherein the not cross-linked polymer is loaded into the composite from organic solution, possibly together with the drug. Pharmaceutical compositions comprising said composite in combination with pharmaceutical acceptable excipients are also described herein.Type: ApplicationFiled: December 22, 2011Publication date: October 17, 2013Applicant: APTALIS PHARMA LIMITEDInventors: Paolo Gatti, Italo Colombo, Dario Gervasoni, Vincenza Pironti, Lia Alborghetti, Flavio Fabiani, Luigi Boltri
-
Publication number: 20130252818Abstract: An amorphous formulation of a herbicidal or pesticidal substance includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a herbicidal or pesticidal substance or a cation precursor that is a herbicidal or pesticidal substance.Type: ApplicationFiled: March 25, 2013Publication date: September 26, 2013Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
-
Patent number: 8541400Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: GrantFiled: August 4, 2005Date of Patent: September 24, 2013Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
-
Patent number: 8524748Abstract: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: October 7, 2009Date of Patent: September 3, 2013Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Thomas Jon Seiders, Jeannie M. Arruda, Jeffrey Roger Roppe
-
Publication number: 20130210883Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.Type: ApplicationFiled: March 15, 2013Publication date: August 15, 2013Inventors: Johannes Grillari, Rolf Breinbauer, Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Elisabeth Schraml, Klaus Fortschegger, Regina Grillari
-
Publication number: 20130202657Abstract: The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or particles containing pharmaceutically active agents. The foam may comprise a pharmaceutically acceptable polymeric carrier. In some cases, the foam or particle has an unexpectedly high specific surface area. A high specific surface area may, in some cases, facilitate delivery or release of the pharmaceutically active agent when the foam or particles made from the foam (e.g., by milling) are administered to a subject. The foam may also exhibit a relatively high loading of the pharmaceutically active agent. In some cases, the foam may be a microcellular foam. In one set of embodiments, the foam is created using a supercritical fluid, such as supercritical C02.Type: ApplicationFiled: May 20, 2011Publication date: August 8, 2013Applicants: BASF SE, President and Fellows of Harvard CollegeInventors: Kosta Ladavac, Rodrigo E. Guerra, David Kaz, Vinothan Manoharan, Jens B. Rieger, Roland S. Koltzenburg, David A. Weitz
-
Patent number: 8501759Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.Type: GrantFiled: December 31, 2009Date of Patent: August 6, 2013Assignee: Fournier Laboratories Ireland LimitedInventor: Eric Bruckert